What is it about?
Salivary duct carcinoma is one of the pathological types of salivary gland cancer, which is characterized by HER2 expression and AR expression. Trastuzumab plus docetaxel is effective and safe treatment option for HER2 positive salivary gland cancer.
Featured Image
Photo by Spencer Davis on Unsplash
Why is it important?
There has been no treatment option for recurrent or metastatic salivary gland cancer. From the results of this phase II trial, trastuzumab plus docetaxel has become an important treatment option for HER2 positive salivary gland cancer.
Perspectives
Further investigations are essential to exploring treatment options for the patients refractory to trastuzumab plus docetaxel.
Naomi Kiyota
Kobe University Hospital
Read the Original
This page is a summary of: Multicenter phase II trial of trastuzumab and docetaxel for HER2-positive salivary gland cancer, Japanese Journal of Clinical Oncology, June 2025, Oxford University Press (OUP),
DOI: 10.1093/jjco/hyaf106.
You can read the full text:
Contributors
The following have contributed to this page
